KalVista Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2011-01-01

Employees: 150

Market Cap: $546.2M

Website: http://www.kalvista.com

Introduction: KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Clinical Trials

Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

Conditions: Hereditary Angioedema

First Posted Date: 2024-10-07

Last Posted Date: 2024-10-07

Lead Sponsor: KalVista Pharmaceuticals, Ltd.

Registration Number: NCT06628713

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Phase 3

Recruiting

Conditions: Hereditary Angioedema

Interventions: Drug: KVD900 75 mg
Drug: KVD900 150 mg
Drug: KVD900 300 mg

First Posted Date: 2024-06-20

Last Posted Date: 2024-12-27

Lead Sponsor: KalVista Pharmaceuticals, Ltd.

Target Recruit Count: 24

Registration Number: NCT06467084

Locations: 🇮🇹
KalVista Investigative Site, Rome, Italy

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Phase 3

Recruiting

Conditions: Hereditary Angioedema

Interventions: Drug: KVD900 600 mg

First Posted Date: 2022-08-23

Last Posted Date: 2025-01-08

Lead Sponsor: KalVista Pharmaceuticals, Ltd.

Target Recruit Count: 12

Registration Number: NCT05511922

Locations: 🇬🇧
KalVista Investigative Site, London, United Kingdom
🇺🇸
Kalvista Investigative Site, Hershey, Pennsylvania, United States
🇬🇧
KalVista Investgative Site, Frimley, United Kingdom

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Phase 3

Active, not recruiting

Conditions: Hereditary Angioedema

Interventions: Drug: KVD900 600 mg
Drug: KVD900 300 mg

First Posted Date: 2022-08-18

Last Posted Date: 2024-12-27

Lead Sponsor: KalVista Pharmaceuticals, Ltd.

Target Recruit Count: 145

Registration Number: NCT05505916

Locations: 🇯🇵
KalVista Investgative Site, Tokyo, Japan
🇬🇧
KalVista Investigative Site, London, United Kingdom
🇿🇦
Kalvista Investigative Site, Cape Town, South Africa

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Phase 3

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: KVD900 600 mg
Drug: KVD900 300 mg
Drug: Placebo

First Posted Date: 2022-03-02

Last Posted Date: 2024-07-19

Lead Sponsor: KalVista Pharmaceuticals, Ltd.

Target Recruit Count: 136

Registration Number: NCT05259917

Locations: 🇯🇵
KalVista Investgative Site, Chiba-shi, Japan
🇬🇧
KalVista Investigative Site, London, United Kingdom
🇬🇷
Kalvista Investigative Site, Athens, Greece

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Phase 1

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: KVD824
Drug: Placebo to KVD824

First Posted Date: 2022-01-05

Last Posted Date: 2022-02-17

Lead Sponsor: KalVista Pharmaceuticals, Ltd.

Target Recruit Count: 108

Registration Number: NCT05178355

Locations: 🇬🇧
KalVista Investigative Site, Merthyr Tydfil, United Kingdom

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Phase 1

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: KVD824 Prototype 1 modified-release tablet
Drug: KVD824 Prototype 2 modified-release tablet
Drug: Placebo to KVD824 Prototype 1
Drug: KVD824 Immediate-Release Capsule
Drug: KVD824 Prototype 3 modified-release tablet